Alkermes(US:ALKS)2025-07-29 12:00Q2 2025 Financial Performance - Total revenue decreased to $390.7 million from $399.1 million in Q2 2024[7] - GAAP net income decreased to $87.1 million from $91.4 million in Q2 2024[7] - GAAP earnings per share (diluted) decreased to $0.52 from $0.53 in Q2 2024[7] - Adjusted EBITDA decreased to $126.5 million from $135.3 million in Q2 2024[10] - The decrease in revenue and profitability reflects the expiration of royalty on U S net sales of INVEGA SUSTENNA® in August 2024[8, 11, 12] Q2 2025 Revenue Breakdown - Total proprietary net sales increased to $307.2 million from $269.3 million in Q2 2024[12] - VIVITROL® net sales were $121.7 million, compared to $111.9 million in Q2 2024[12] - ARISTADA® net sales were $101.3 million, compared to $86.0 million in Q2 2024[12] - LYBALVI® net sales were $84.3 million, compared to $71.4 million in Q2 2024[12] - Manufacturing & Royalty Revenue decreased to $83.4 million from $129.9 million in Q2 2024[12] 2025 Financial Expectations - Total revenues are expected to be between $1340 million and $1430 million[13] - GAAP net income is projected to be between $175 million and $205 million[13] - Adjusted EBITDA is projected to be between $310 million and $340 million[13] - VIVITROL® net sales are expected to be between $440 million and $460 million[16] - ARISTADA® net sales are expected to be between $335 million and $355 million[16] - LYBALVI® net sales are expected to be between $320 million and $340 million[16]